Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana
Journal of Illicit Economies and Development · 02.12.2022 · 4 (2) · 204-222
DOI: 10.31389/jied.122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Illicit Economies and Development, erschienen am 02.12.2022. Verfasst von Fernando Montero und 2 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University, US. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIMH NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Columbia University, US.
- University of California, Los Angeles, US.
ORCID-Profile: Fernando Montero, Philippe Bourgois, Joseph Friedman
Förderung
- NIGMS NIH HHS
- NIMH NIH HHS
- NIDA NIH HHS
- NIH
Zitieren
APA
Montero, F., Bourgois, P., & Friedman, J. (2022). Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. Journal of Illicit Economies and Development, 4(2), 204-222. https://doi.org/10.31389/jied.122
Vancouver
Montero F, Bourgois P, Friedman J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. Journal of Illicit Economies and Development. 2022;4(2):204-222. doi:10.31389/jied.122
BibTeX
@article{Montero2022,
author = {Montero, Fernando and Bourgois, Philippe and Friedman, Joseph},
title = {Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana},
journal = {Journal of Illicit Economies and Development},
year = {2022},
volume = {4},
number = {2},
pages = {204--222},
doi = {10.31389/jied.122}
}
EUVIMED